866775-18-0

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 3-amino-6-bromo-5-(trifluoromethyl)picolinate is used as an intermediate in the synthesis of pharmaceuticals for its potential applications in the development of new drugs. Its unique chemical structure allows it to be a building block for the preparation of various heterocyclic compounds, which are important in the creation of medicinal agents.
Used in Agrochemical Industry:
In the agrochemical industry, Methyl 3-amino-6-bromo-5-(trifluoromethyl)picolinate is also utilized as an intermediate in the synthesis of agrochemicals. Its properties make it suitable for the development of new compounds that can be used in agriculture for pest control and crop protection.

Upstream product

• 655235-65-7 methyl 3-chloro-5-(trifluoromethyl)pyridine-2-carboxylate 
• 72587-15-6 2-chloro-3-nitro-5-(trifluoromethyl)pyridine 
• 1211515-30-8 3-amino-5-(trifluoromethyl)picolinonitrile 
• 1214336-90-9 3-amino-6-(2,6-difluorophenyl)-5-trifluoromethyl-2-pyridinecarboxylicacid 
• 866775-17-9 3-amino-5-trifluoromethyl-pyridine-2-carboxylic acid methyl ester 
• 866775-16-8 3-nitro-5-trifluoromethyl-pyridine-2-carbonitrile 
• 33252-64-1 3-nitro-5-trifluoromethylpyridin-2-ol 

Downstream Products

• 1334547-23-7 3-amino-6-(2,4-dichlorophenyl)-5-trifluoromethylpyridine-2-carboxylic acid methyl ester 
• 1334546-83-6 3-amino-6-(2,4-dichlorophenyl)-5-trifluoromethylpyridine-2-carboxylic acid 
• 1334547-21-5 3-amino-6-(4-fluorophenyl)-5-trifluoromethylpyridine-2-carboxylic acid 
• 1334546-80-3 3-amino-6-(4-fluorophenyl)-5-trifluoromethylpyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl)amide 
• 1427400-35-8 methyl 3-amino-6-(4-fluorophenyl)-5-(trifluoromethyl)picolinate 
• 1427400-25-6 3-amino-6-(4-fluorophenyl)-N-(1H-pyrazol-3-yl)-5-(trifluoromethyl)picolinamide 
• 1427262-80-3 (R)-2-(5-(amino(phenyl)methyl)-1,3,4-oxadiazol-2-yl)-6-bromo-5-(trifluoromethyl)pyridin-3-amine 
• 1427262-83-6 (R)-benzyl (5-(3-amino-6-bromo-5-(trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(phenyl)methylcarbamate 
• 1427262-81-4 (R)-benzyl 2-(2-(3-amino-6-bromo-5-(trifluoromethyl)picolinoyl)hydrazinyl)-2-oxo-1-phenylethylcarbamate 
• 1427262-60-9 2-(5-benzyl-1,3,4-oxadiazol-2-yl)-6-bromo-5-(trifluoromethyl)pyridin-3-amine 
• 1427262-61-0 3-amino-6-bromo-N'-(2-phenylacetyl)-5-(trifluoromethyl)picolinohydrazide 

Relevant academic research and scientific papers

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel are established as the primary causative factor in the devastating lung disease cystic fibrosis (CF). More recently, cigarette smoke exposure has been shown to be asso

Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis

The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS

The present invention provides pyridin-oxadiazole/thiadiazole derivatives of Formula I wherein A is N or CR 4a; and (ii) or (iii) which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

PYRIDINE AMIDE DERIVATIVES

The present invention provides pyridine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory

Pyridine amide derivatives

The present invention provides pyridine amide derivatives which re? store or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, resp

PYRIDINE/PYRAZINE AMIDE DERIVATIVES

The present invention provides pyridine/pyrazine amide derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthm

N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES

A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Ra, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in

Pyridine and Pyrazine derivative for the Treatment of CF

The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA

The present invention discloses compounds of formula I wherein A, n, m, j, q, K, W, X, K, Z, R1, R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.